In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment

Russell Mark Morphew, Neil Douglas MacKintosh, Elizabeth Helen Hart, Mark Prescott, E. James LaCourse, Peter Michael Brophy

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

18 Dyfyniadau (Scopus)
193 Wedi eu Llwytho i Lawr (Pure)

Crynodeb

The parasitic flatworm Fasciola hepatica is a global food security risk. With no vaccines, the sustainability of triclabendazole (TCBZ) is threatened by emerging resistance. F. hepatica excretory/secretory (ES) products can be detected in host faeces and used to estimate TCBZ success and failure. However, there are no faecal based molecular diagnostics dedicated to assessing drug failure or resistance to TCBZ in the field. Utilising in vitro maintenance and sub-proteomic approaches two TCBZ stress ES protein response fingerprints were identified: markers of non-killing and lethal doses. This study provides candidate protein/peptide biomarkers to validate for detection of TCBZ failure and resistance.
Iaith wreiddiolSaesneg
Tudalennau (o-i)85-99
Nifer y tudalennau15
CyfnodolynEuPA Open Proteomics
Cyfrol3
Dyddiad ar-lein cynnar12 Maw 2014
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - Meh 2014

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn